• 1. Department of Nephrology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621000, P. R. China;
  • 2. School of Clinical Medicine, Chengdu Medical College, Chengdu, Sichuan 610500, P. R. China;
  • 3. School of Clinical Medicine, Guangxi Medical University, Nanning, Guangxi 530000, P. R. China;
  • 4. Department of Nephrology, Beichuan Qiang Autonomous County People’s Hospital, Beichuan, Sichuan 622750, P. R. China;
DAI Xiaoyu, Email: daixy001@163.com
Export PDF Favorites Scan Get Citation

In recent years, the incidence of hyperlipidemia acute pancreatitis (HLAP) has been increasing year by year, but its pathogenesis has not been completely clear. There are many clinical treatment methods for HLAP, such as lipid-lowering drugs, low molecular weight heparin, insulin, and plasma exchange. Actively reducing serum triglyceride is the core of treatment. Plasma exchange can quickly and effectively reduce the level of triglyceride, and its application in the treatment of HLAP is gradually increasing. This article reviews the recent advances in the pathogenesis, clinical characteristics, diagnosis, and treatment of HLAP, focusing on the mechanism, indications, timing, and disadvantages of plasma exchange therapy for HLAP.

Citation: PAN Xiaoyan, DAI Xiaoyu, SHI Zhuohua, REN Kaiyan. Progress in the treatment of hyperlipidemia acute pancreatitis. West China Medical Journal, 2022, 37(1): 120-124. doi: 10.7507/1002-0179.202106046 Copy

  • Previous Article

    Application of rehabilitation training in lung cancer patients during chemotherapy
  • Next Article

    Application value of probiotics in regulating proton pump inhibitor-induced gastrointestinal microecological disorders